Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).

Chavan A, Schumann-Binarsch S, Luthe L, Nickau B, Elsässer A, Kühnel T, Geisthoff U, Köhne H.

Vasa. 2013 Mar;42(2):106-10. doi: 10.1024/0301-1526/a000253.

PMID:
23485837
2.

Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.

Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F.

JAMA. 2012 Mar 7;307(9):948-55. doi: 10.1001/jama.2012.250.

PMID:
22396517
3.

Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.

Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L.

Liver Transpl. 2008 Feb;14(2):210-3. doi: 10.1002/lt.21417.

4.

Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.

Dheyauldeen S, Østertun Geirdal A, Osnes T, Vartdal LS, Dollner R.

Laryngoscope. 2012 Jun;122(6):1210-4. doi: 10.1002/lary.23303. Epub 2012 May 7.

PMID:
22565282
5.

Hereditary hemorrhagic telangiectasia/avastin.

Davidson TM, Olitsky SE, Wei JL.

Laryngoscope. 2010 Feb;120(2):432-5. doi: 10.1002/lary.20757.

PMID:
19998344
6.

ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.

Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F.

MAbs. 2014 May-Jun;6(3):794-9. doi: 10.4161/mabs.28025. Epub 2014 Jan 30.

7.

Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study.

Dupuis-Girod S, Chesnais AL, Ginon I, Dumortier J, Saurin JC, Finet G, Decullier E, Marion D, Plauchu H, Boillot O.

Liver Transpl. 2010 Mar;16(3):340-7. doi: 10.1002/lt.21990.

8.

Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.

Karnezis TT, Davidson TM.

Laryngoscope. 2012 Mar;122(3):495-7. doi: 10.1002/lary.22501. Epub 2011 Dec 6.

PMID:
22147664
9.

Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.

Chen S 4th, Karnezis T, Davidson TM.

Laryngoscope. 2011 Mar;121(3):644-6. doi: 10.1002/lary.21345. Epub 2010 Nov 11.

PMID:
21344447
10.

A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.

Rohrmeier C, Sachs HG, Kuehnel TS.

Eur Arch Otorhinolaryngol. 2012 Feb;269(2):531-6. doi: 10.1007/s00405-011-1721-9. Epub 2011 Jul 31.

PMID:
21805356
11.

Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.

Brinkerhoff BT, Choong NW, Treisman JS, Poetker DM.

Am J Otolaryngol. 2012 May-Jun;33(3):349-51. doi: 10.1016/j.amjoto.2011.07.012. Epub 2011 Sep 13.

PMID:
21917353
12.

Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.

Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR.

JAMA. 2016 Sep 6;316(9):943-51. doi: 10.1001/jama.2016.11724.

PMID:
27599329
13.

Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.

Kanellopoulou T, Alexopoulou A.

Expert Opin Biol Ther. 2013 Sep;13(9):1315-23. doi: 10.1517/14712598.2013.813478. Epub 2013 Jul 2.

PMID:
23815519
14.

Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.

Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G.

MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693.

15.

Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.

Kochanowski J, Sobieszczańska M, Tubek S, Żurek M, Pawełczak J.

Hum Vaccin Immunother. 2015;11(3):680-1. doi: 10.1080/21645515.2015.1011960.

16.

Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.

Karnezis TT, Davidson TM.

Laryngoscope. 2011 Mar;121(3):636-8. doi: 10.1002/lary.21415. Epub 2010 Dec 16.

PMID:
21344445
17.

The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab.

Alderman C, Corlett J, Cullis J.

Br J Haematol. 2013 Aug;162(4):547-8. doi: 10.1111/bjh.12377. Epub 2013 May 14. No abstract available.

PMID:
23672440
18.

[Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].

Bennesser Alaoui H, Lehraiki M, Hamaz S, El Attar N, Fakhreddine N, Serraj K.

Rev Med Interne. 2015 Sep;36(9):623-5. doi: 10.1016/j.revmed.2014.11.004. Epub 2015 Jan 13. French.

PMID:
25595875
19.

Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, Greil R, Weiss L.

Wien Klin Wochenschr. 2017 Feb;129(3-4):141-144. doi: 10.1007/s00508-016-1124-4.

20.

[Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].

Rohrmeier C, Kühnel TS.

HNO. 2012 Nov;60(11):1003-6. doi: 10.1007/s00106-011-2458-x. German.

PMID:
22706563

Supplemental Content

Support Center